A phase II study of elacytarabine plus idarubicin as second course remission-induction therapy in patients with acute myeloid leukemia.

摘要: TPS207 Background: Elacytarabine is a fatty acid derivative (elaidic ester) of the antimetabolite cytarabine,which widely used in treatment AML. Preclinical data has shown that entry cytarabine into tumour cells dependent on expression specific membrane transporter proteins, particularly hENT1 (human equilibrative nucleoside 1). Decreased major factor resistance childhood AML (Hubeek et al., 2005). For elacytarabine independent from transporters and offers therefore an opportunity for treating patients not likely to benefit cytarabine. In phase I studies activity been observed with refractory/relapsed AML, as monotherapy well combination idarubicin. Synergy anthracycline vitro, demonstrated safety profile similar Methods: P...